Ground-breaking aspirin trial extended
The ASPREE-XT trial will track outcomes, including cancer deaths
6th August 2019
By Kemal Atlay
Thousands of elderly patients who took part in the landmark ASPREE trial of aspirin for primary prevention will continue to be monitored for a further five years in an observational study.